Evidence map›Paper›PMID 40238887›Full record

ArticleScience advances2025

Permissive central tolerance plus defective peripheral checkpoints license pathogenic memory B cells in CASPR2-antibody encephalitis.

Bo Sun, Dominique Fernandes, John Soltys, Anne-Kathrin Kienzler, Sofija Paneva, Ruby Harrison, Sudarshini Ramanathan, Anna L Harrison, Mateusz Makuch, Miriam L Fichtner and 32 more

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Autoimmune encephalitis.Nature reviews. Disease primers · 2025
    Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

42 authors.

Bo SunNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0002-5507-6657
Dominique FernandesCNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.ORCID 0000-0001-5114-6227
John SoltysNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0009-0008-4981-7755
Anne-Kathrin KienzlerNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0002-3082-9210
Sofija PanevaNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0002-0151-8763
Ruby HarrisonNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0003-2985-8652
Sudarshini RamanathanNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.
Anna L HarrisonNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0009-0006-4959-020X
Mateusz MakuchNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.
Miriam L FichtnerDepartments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-0107-4103
Robert F DonatRadcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.
Deniz AkdenizNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.
Halwan BayuanggaNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0003-0179-1644
Min Gyu ImNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0009-0009-1509-6408
Robyn WilliamsNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.
Ana VasconcelosCNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.ORCID 0000-0002-3168-6274
Selina ThomsenNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.
Andrew FowerNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0003-0414-2367
Ruyue SunNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.
Hannah FoxNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0003-4667-4345
Victor MgbachiNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.
Alexander DaviesNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0003-0072-1708
Mandy TsengNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0002-8388-9292
Adam HandelNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0001-8385-6346
Mark KellyNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0001-7214-5039
Meng ZhaoNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0002-9967-7075
James BancroftCellular Imaging Core Facility, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, OX3 7BN, Oxford, UK.ORCID 0000-0002-6644-3432
Rachael Bashford-RogersDepartment of Biochemistry, University of Oxford, South Parks Road, Oxford, 0X1 3QU, UK.
John V PluvinageUCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA.ORCID 0000-0002-9607-2783
Ravi DandekarUCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA.ORCID 0000-0002-2930-3043
Bonny D AlvarengaUCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA.ORCID 0000-0001-7922-9454
Lynn B DustinKennedy Institute of Rheumatology, University of Oxford, Roosevelt Drive, Headington, Oxford, OX3 7FY, UK.ORCID 0000-0002-2619-1867
Simon RinaldiNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0003-2039-3457
Ray OwensRosalind Franklin Institute, Harwell Science Campus, Didcot, OX11 0QX, UK.ORCID 0000-0002-3705-2993
Daniel AnthonyDepartment of Pharmacology, University of Oxford, Oxford, UK.ORCID 0000-0003-1380-6655
David L BennettNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0002-7996-2696
Patrick WatersNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.
Simon J DavisRadcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.ORCID 0000-0002-2280-1170
Michael R WilsonUCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA.ORCID 0000-0002-8705-5084
Kevin C O'ConnorDepartments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-7056-419X
Ana Luisa CarvalhoCNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.ORCID 0000-0001-8368-6666
Sarosh R IraniNuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, Oxford, UK.ORCID 0000-0002-7667-9748

Funding

Autoimmune Encephalitis - Ataxia and Psychiatric Disease: Identifying and Characterizing Novel Antibody TargetsR01MH122471 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOSEPH L. DERISI, SAMUEL JEREMY PLEASURE · 2020 to 2026
$4.7M
NIMH NIH HHS R01 MH122471Wellcome Trust
6 · The paper itself

Abstract

Autoantibody-mediated diseases targeting one autoantigen provide a unique opportunity to comprehensively understand the development of disease-causing B cells and autoantibodies. Convention suggests that such autoreactivities are generated during germinal center reactions. Here, we explore earlier immune checkpoints, focusing on patients with contactin-associated protein-like 2 (CASPR2)-autoantibody encephalitis. In both disease and health, high (~0.5%) frequencies of unmutated CASPR2-reactive naïve B cells were identified. By contrast, CASPR2-reactive memory B cells were exclusive to patients, and their B cell receptors demonstrated affinity-enhancing somatic mutations with pathogenic effects in neuronal cultures and mice. The unmutated, precursor memory B cell receptors showed a distinctive balance between strong CASPR2 reactivity and very limited binding across the remaining human proteome. Our results identify permissive central tolerance, defective peripheral tolerance, and autoantigen-specific tolerance thresholds in humans as sequential steps that license CASPR2-directed pathology. By leveraging the basic immunobiology, we rationally direct tolerance-restoring approaches, with an experimental paradigm applicable across autoimmunity.

Indexed as

AutoantibodiesB-LymphocytesCentral ToleranceEncephalitisMembrane ProteinsMemory B CellsNerve Tissue ProteinsAnimalsAutoantigensFemaleHumansMaleMiceReceptors, Antigen, B-CellAutoantibodiesAutoantigensCNTNAP2 protein, humanMembrane ProteinsNerve Tissue ProteinsReceptors, Antigen, B-Cell

Identifiers

PMID40238887
PMCPMC12002137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.